Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 3,411 matching trials from the live ClinicalTrials.gov search.
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Methemoglobinemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
chemotherapy, dapsone, medical chart review, assessment of therapy complications
Drug · Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Nashville, Tennessee
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
65
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Conditions
Leukemia
Interventions
recombinant interferon alfa, amifostine trihydrate, bromodeoxyuridine, cytarabine, idarubicin, idoxuridine, isotretinoin, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
0 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
4
States / cities
Chicago, Illinois • Kankakee, Illinois
Conditions
Chronic Myeloid Leukemia
Interventions
ponatinib, imatinib (Gleevec/ Glivec)
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Burbank, California • Los Angeles, California • Pleasant Hill, California + 53 more
Conditions
Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor
Interventions
Enoblituzumab
Drug
Lead sponsor
MacroGenics
Industry
Eligibility
1 Year to 35 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more
Conditions
Osteosarcoma, Medulloblastoma, Sarcoma, Ewing's, Neuroblastoma (Measurable Disease), Neuroblastoma (Metaiodobenzylguanidine, Positive Evaluable), Rhabdomyosarcoma, Ependymoma, Non-brainstem High-grade Glioma
Interventions
pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 22 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Arcadia, California
Conditions
Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
15
States / cities
Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more
Conditions
Leukemia, Lymphoma
Interventions
arsenic trioxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
47
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 38 more
Conditions
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
6 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
29
States / cities
Birmingham, Alabama • Duarte, California • Oxnard, California + 24 more
Conditions
Osteosarcoma
Interventions
SCRI-E2CAR_EGFRtv1, UB_TT170
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma
Interventions
sodium thiosulfate, examination
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more
Conditions
Solid Tumor Malignancy
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
44
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
Interventions
MK-0482
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Buffalo, New York • Houston, Texas
Conditions
Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
umbilical cord blood transplantation
Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Conditions
Sarcoma, Ewing, Neoplasm Metastasis
Interventions
Abemaciclib, Irinotecan, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 39 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Indianapolis, Indiana + 2 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Leukemia, Lymphoma, Oral Complications
Interventions
filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, peripheral blood stem cell transplantation, quality-of-life assessment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Conditions
Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
Interventions
birinapant, Azacitidine, Placebo
Drug
Lead sponsor
TetraLogic Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
46
States / cities
Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 39 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Health Telemonitoring, Quality-of-Life Assessment, Questionnaire Administration, Supportive Care
Device · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma
Interventions
Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation, Fludarabine, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Thiotepa
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • Seattle, Washington